Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This review discusses various strategies for drug repurposing in tuberculosis treatment, highlighting significant potential but reports no new clinical results.

This report describes a case of acute liver injury in a woman following the use of Shen-Min, a herbal hair growth supplement, highlighting a potential link to acute hepatitis.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This article reviews the dermatologic conditions associated with hemodialysis, such as pruritus, xerosis cutis, and skin infections, and does not present new findings.

This study suggests that two approved drugs may inhibit the SARS-CoV-2 helicase based on significant activity in laboratory models, offering hope for potential COVID-19 treatments.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This review outlines how peptidyl arginine deiminases (PADIs) and protein citrullination are involved in hair follicle regeneration and inflammatory alopecia, but presents no new clinical findings.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

This review examines the spontaneous clearance of hepatitis C virus and factors such as IL-28B genetic polymorphism, which have been associated with this outcome, and reports no new clinical results.

This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.

This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

This study found that oral contraceptive pills containing cyproterone acetate and drospirenone were more effective at reducing hirsutism in women with PCOS than those containing levonorgestrel over a 6-month period.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

This case study observed that long-term itraconazole and budesonide use in a cystic fibrosis patient led to iatrogenic Cushing's syndrome due to inhibited metabolic clearance of budesonide, suggesting a need for regular adrenal insufficiency monitoring in such treatments.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

In this study, researchers developed a hyaluronic acid-coated copper peroxide nano-antimicrobial system that demonstrated precise antimicrobial activity and accelerated wound healing by releasing reactive oxygen species in response to bacterial enzymes, in both laboratory and animal tests.

This review outlines the strategies for managing TB-IRIS in HIV patients, emphasizing early detection, prevention, and appropriate treatment to reduce morbidity and mortality.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This study found that treprostinil, a prostacyclin analog, significantly delayed fibroblast migration from healthy donors but did not affect fibroblast migration derived from diabetic foot ulcers.

This article discusses ongoing and planned clinical chemoprevention trials for various agents and combinations but reports no new results; it highlights promising new agents and the evolving focus on molecular pathways.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.

In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

This case study highlights that primary biliary cholangitis in a patient with systemic lupus erythematosus can respond well to ursodeoxycholic acid therapy, and anti-DFS70 findings may require further evaluation for other nonsystemic autoimmune conditions.